Background: Early cancer detection could identify tumors at a time when outcomes are superior and treatment is less morbid. This prospective case-control sub-study (from NCT02889978 and NCT03085888) assessed the performance of targeted methylation analysis of circulating cell-free DNA (cfDNA) to detect and localize multiple cancer types across all stages at high specificity. Participants and methods: The 6689 participants [2482 cancer (>50 cancer types), 4207 non-cancer] were divided into training and validation sets. Plasma cfDNA underwent bisulfite sequencing targeting a panel of >100 000 informative methylation regions. A classifier was developed and validated for cancer detection and tissue of origin (TOO) localization. Results: Performance was consistent in training and validation sets. In validation, specificity was 99.3% [95% confidence interval (CI): 98.3% to 99.8%; 0.7% false-positive rate (FPR)]. Stage I–III sensitivity was 67.3% (CI: 60.7% to 73.3%) in a pre-specified set of 12 cancer types (anus, bladder, colon/rectum, esophagus, head and neck, liver/bile-duct, lung, lymphoma, ovary, pancreas, plasma cell neoplasm, stomach), which account for ~63% of US cancer deaths annually, and was 43.9% (CI: 39.4% to 48.5%) in all cancer types. Detection increased with increasing stage: in the pre-specified cancer types sensitivity was 39% (CI: 27% to 52%) in stage I, 69% (CI: 56% to 80%) in stage II, 83% (CI: 75% to 90%) in stage III, and 92% (CI: 86% to 96%) in stage IV. In all cancer types sensitivity was 18% (CI: 13% to 25%) in stage I, 43% (CI: 35% to 51%) in stage II, 81% (CI: 73% to 87%) in stage III, and 93% (CI: 87% to 96%) in stage IV. TOO was predicted in 96% of samples with cancer-like signal; of those, the TOO localization was accurate in 93%. Conclusions: cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies.
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
Min Liu,G. Oxnard,E. Klein,C. Swanton,C. Swanton,M. Seiden,Minetta C. Liu,G. Oxnard,E. Klein,David Smith,D. Richards,Timothy J. Yeatman,A. Cohn,R. Lapham,J. Clement,A. Parker,M. Tummala,K. McIntyre,M. Sekeres,A. Bryce,Robert W. Siegel,Xuezhong Wang,David P. Cosgrove,N. Abu-Rustum,J. Trent,D. Thiel,C. Becerra,Manish Agrawal,L. Garbo,J. Giguere,Ross M. Michels,R. Harris,S. Richey,T. McCarthy,D. Waterhouse,F. Couch,S. Wilks,A. Krie,R. Balaraman,A. Restrepo,M. Meshad,K. Rieger-Christ,T. Sullivan,Christine M. Lee,D. R. Greenwald,William Oh,C. Tsao,N. Fleshner,H. Kennecke,M. Khalil,D. Spigel,Atisha Manhas,B. Ulrich,P. Kovoor,C. Stokoe,Jay Courtright,H. Yimer,Timothy G. Larson,C. Swanton,C. Swanton,M. Seiden,S. Cummings,Farnaz Absalan,G. Alexander,B. Allen,Hamed Amini,Alex Aravanis,Siddhartha Bagaria,L. Bazargan,J. Beausang,Jennifer R. Berman,Craig M. Betts,A. Blocker,J. Bredno,Calef Robert Abe Paine,G. Cann,J. Carter,Christopher Chang,H. Chawla,Xiaoji Chen,Tom C. Chien,D. Civello,Konstantin Davydov,V. Demas,Mohini Desai,Zhao Dong,Saniya Fayzullina,Alexander P. Fields,D. Filippova,Peter Freese,E. Fung,S. Gnerre,S. Gross,M. Halks-Miller,M. Hall,A. Hartman,C. Hou,E. Hubbell,N. Hunkapiller,K. Jagadeesh,A. Jamshidi,R. Jiang,B. Jung,Taehyung Kim,R. Klausner,K. Kurtzman,M. Lee,Wendy-Ling Lin,J. Lipson,Hai Liu,Qinwen Liu,M. Lopatin,T. Maddala,M. C. Maher,Collin Melton,Andrea Mich,S. Nautiyal,Jonathan Newman,Joshua Newman,Nicula Virgil,Cosmos Nicolaou,Ongjen Nikolic,Wenying Pan,Shilpen A. Patel,Sarah A Prins,R. Rava,Neda Ronaghi,O. Sakarya,R. Satya,Jan Schellenberger,Eric Scott,A. Sehnert,R. Shaknovich,A. Shanmugam,K. Shashidhar,Ling Shen,Archana Shenoy,S. Shojaee,P. Singh,Kristan K. Steffen,Susan Tang,J. Toung,Anton Valouev,Oliver Venn,R. Williams,Tony Wu,Huihong Xu,Christopher Yakym,X. Yang,J. Yecies,A.S.M. Yip,J. Youngren,J. Yue,Jingyang Zhang,Lily Zhang,Lori Zhang,N. Zhang,C. Curtis,D. Berry
Published 2020 in Annals of Oncology
ABSTRACT
PUBLICATION RECORD
- Publication year
2020
- Venue
Annals of Oncology
- Publication date
2020-03-30
- Fields of study
Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-28 of 28 references · Page 1 of 1